Trial Profile
A MULTICENTER, OPEN LABEL, RANDOMIZED PHASE II STUDY COMPARING DARATUMUMAB combined with BORTEZOMIB-CYCLOPHOSPHAMIDE- DEXAMETHASONE (Dara-VCd) VERSUS THE ASSOCIATION OF BORTEZOMIB-THALIDOMIDE-DEXAMETHASONE (VTd) AS PRE TRANSPLANT INDUCTION AND POST TRANSPLANT CONSOLIDATION, BOTH FOLLOWED BY A MAINTENANCE PHASE WITH IXAZOMIB ALONE OR IN COMBINATION WITH DARATUMUMAB, IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) YOUNG PATIENTS eligible for AUTOLOGOUS STEM CELL TRANSPLANTATION
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Dec 2023
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Daratumumab (Primary) ; Daratumumab (Primary) ; Ixazomib (Primary) ; Cyclophosphamide; Dexamethasone; Thalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms DaraVCd
- 12 Dec 2018 New trial record